|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||10.79 - 11.49|
|52 Week Range||9.83 - 20.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Details the CEO buys this past week for the following companies: Continental Resources, New Fortress Energy, Athenex, FS KKR Capital and Federal Agricultural Mortgage
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The price of the stock has decreased by 0.16% since.
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Warning! GuruFocus has detected 3 Warning Signs with ATNX.
Results from the Phase 3 study of Athenex's leading drug candidate will be published in the middle of this year, potentially signaling to the world the arrival of its technology.
On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported ...
Shares of biotech Athenex, Inc. rose 3.8% in premarket trade Monday after the company announced that two Phase 3 studies of KX2-391, an ointment for the treatment of actinic keratosis, had met their primary endpoints. Actinic keratosis is a skin condition caused by exposure to the sun's ultraviolet rays, resulting in patches of thick, scaly skin. Left untreated, the lesions can progress to skin cancer. In one study of 351 patients, 44% of patients receiving KX2-391 cleared their actinic keratosis lesions after 57 days, compared with 5% of those in the control group. In the second study, also of 351 patients, 54% of patients getting the treatment cleared their lesions, compared with 13% of patients in the control group. Side effects were mild to moderate, the company said, and were usually local skin reactions causing itchiness or pain. Shares of Athenex have fallen 16.3% in the year to date, while the S&P 500 has gained 4.2%.
The number was inflated by the surging ACV Auctions, an online platform for wholesale car auctions, which was founded in 2014 and closed Series C and D venture capital rounds last year that totaled $124 million. It is undoubtedly the biggest story in Buffalo tech, but it’s not the sole reason 2018 was a record-breaking year. The portfolio of startups that received funding in Buffalo last year reflect the city’s economic diversity, along with the development strategies of recent years.
The fast-growing drug development company expects to data this year on its two leading chemotherapy drugs. The pharmaceutical world is watching.
A look at the shareholders of Athenex, Inc. (NASDAQ:ATNX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...
CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 10,000 shares of ATNX on 11/19/2018 at an average price of $11.75 a share.
The Buffalo, New York-based company said it had a loss of 70 cents per share. Losses, adjusted for non-recurring costs, came to 33 cents per share. The biopharmaceutical company posted revenue of $18.4 ...
On a per-share basis, the Buffalo, New York-based company said it had a loss of 58 cents. The biopharmaceutical company posted revenue of $11.6 million in the period. Athenex expects full-year revenue ...
Athenex entered a joint venture with Xiangxue Life Sciences for developing and commercializing T-cell receptor engineered cells (or TCR-T). TCR-T is a cancer immunotherapy technology based on the novel approach to high-affinity TCR developed by Xiangxue Life Sciences.
The majority of Athenex’s revenues in the first quarter came from API sales, commercial product sales, and license fees. License fees and consulting revenues showed the biggest increase, rising from $598,000 in the first quarter of 2017 to $25.01 million in the first quarter.
Athenex (ATNX) believes its ability to overcome challenges associated with the oral delivery of chemotherapy and intravenous delivery through its P-gp inhibitor could offer key potential benefits for patients. These developments could help patients stay on therapy longer, extending the potential to combine with other targeted therapies and immunotherapies that would otherwise be too toxic in combination with chemotherapy. Athenex’s orascovery platform is based on the P-gp pump inhibitor molecule HM30181A, which the company had in-licensed from Hanmi Pharmaceuticals in 2011. Coadministering this molecule with oral paclitaxel is designed to facilitate the oral absorption of paclitaxel.
Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform. Athenex’s Oncology Innovative Platform segment performs proprietary drug research and development. While the segment had incurred a net loss of $28.26 million in the first quarter of 2017, in the first quarter it generated net income of $1.51 million.